

MEDIMMUNE INC /DE
 Form 3/A
 August 11, 2005

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * ^ Lupien Pamela J (Last) (First) (Middle)		2. Date of Event Requiring Statement (Month/Day/Year) 05/19/2005	3. Issuer Name and Ticker or Trading Symbol MEDIMMUNE INC /DE [MEDI]	5. If Amendment, Date Original Filed(Month/Day/Year) 05/31/2005
ONE MEDIMMUNE WAY (Street)			4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) VP, Human Resources	6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
GAITHERSBURG, ^ MD ^ 20878 (City) (State) (Zip)				

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,293	D	^

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable Expiration Date	Title Amount or Number of			

Edgar Filing: MEDIMMUNE INC /DE - Form 3/A

				Shares		(I) (Instr. 5)	
Stock Options (Right to buy)	06/04/2004 ⁽¹⁾	03/04/2014	Common Stock	30,000	\$ 23.45	D	Â
Stock Options (Right to buy)	05/16/2005 ⁽¹⁾	02/16/2015	Common Stock	35,000	\$ 24.17	D	Â
Stock Options (Right to buy)	05/20/2003 ⁽¹⁾	02/20/2013	Common Stock	25,000	\$ 29.34	D	Â
Stock Options (Right to buy)	04/01/2003 ⁽²⁾	04/01/2012	Common Stock	30,000	\$ 39.33	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Lupien Pamela J ONE MEDIMMUNE WAY GAITHERSBURG, MD 20878	Â	Â	Â VP, Human Resources	Â

Signatures

William C. Bertrand, Jr., as attorney-in-fact 08/11/2005

Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (2) Grant exercisable in quarterly installments over a four year period subject to a one year wait period. Four quarters vest upon reaching one year wait period.
- (1) Grant exercisable in quarterly installments over a four year period.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.